| Diffuse Large B-Cell Lymphoma

Columvi vs Rituxan Hycela

Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.

Deep comparison between: Columvi vs Rituxan Hycela with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRituxan Hycela has a higher rate of injection site reactions vs Columvi based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Rituxan Hycela but not Columvi, including UnitedHealthcare

Category

Columvi

Rituxan Hycela

At A Glance

RouteIV infusion

FrequencyEvery 3 weeks

ClassCD20xCD3 bispecific T-cell engager

RouteSC injection

FrequencyEvery 3-4 weeks

ClassCD20-directed antibody

Indications

Diffuse Large B-Cell Lymphoma

Lymphoma, Follicular
Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia

Dosing

Diffuse Large B-Cell Lymphoma Pretreat with obinutuzumab 1,000 mg IV on Cycle 1 Day 1; then administer COLUMVI IV: 2.5 mg step-up dose on Cycle 1 Day 8, 10 mg step-up dose on Cycle 1 Day 15, then 30 mg on Day 1 of Cycles 2-12 (21-day cycles; maximum 12 cycles or until disease progression or unacceptable toxicity).

Lymphoma, Follicular 1,400 mg/23,400 Units SC; for relapsed/refractory FL, once weekly for 3 or 7 weeks following an initial IV rituximab dose (4 or 8 weeks total); for previously untreated FL, on Day 1 of Cycles 2-8 of chemotherapy every 21 days, then maintenance every 8 weeks for 12 doses; for non-progressing FL after CVP, once weekly for 3 weeks every 6 months to a maximum of 16 doses.

Diffuse Large B-Cell Lymphoma 1,400 mg/23,400 Units SC on Day 1 of Cycles 2-8 of CHOP chemotherapy every 21 days for up to 7 cycles following an initial IV rituximab dose at Day 1, Cycle 1 (up to 6-8 cycles total).

Chronic Lymphocytic Leukemia 1,600 mg/26,800 Units SC on Day 1 of Cycles 2-6 in combination with fludarabine and cyclophosphamide every 28 days for 5 cycles following an initial IV rituximab dose at Day 1, Cycle 1 (6 cycles total).

Contraindications

—

Drug Interactions

852View drug interactions

637View drug interactions

Adverse Reactions

Most common (>=20%) Cytokine release syndrome, musculoskeletal pain, rash, fatigue

Serious Cytokine release syndrome, COVID-19 infection, sepsis, tumor flare

Most common (>=20%) Infections, neutropenia, nausea, constipation, cough, fatigue (FL); infections, neutropenia, alopecia, nausea, anemia (DLBCL); infections, neutropenia, nausea, thrombocytopenia, pyrexia, vomiting, injection site erythema (CLL).

Serious Mucocutaneous reactions, hepatitis B reactivation, progressive multifocal leukoencephalopathy, hypersensitivity and administration reactions, tumor lysis syndrome, infections, cardiac arrhythmias, renal toxicity, bowel obstruction and perforation.

Postmarketing Prolonged pancytopenia, fatal cardiac failure, uveitis, viral infections including PML, Kaposi's sarcoma progression, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease.

Pharmacology

Glofitamab-gxbm is a bispecific CD20-directed CD3 T-cell engager that binds CD20 on B cells and CD3 on T cells, causing T-cell activation and proliferation, cytokine secretion, and lysis of CD20-expressing B cells.

Anti-CD20 chimeric murine/human IgG1 monoclonal antibody that binds the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis via complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC); combined with hyaluronidase human, which transiently depolymerizes subcutaneous hyaluronan to enhance rituximab absorption into systemic circulation.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Columvi